Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CDA | P32320 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881950 | 1.00 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL432298 | 1.00 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL432296 | 1.00 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL22972654 | 0.94 | P2RY6 (0.55) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL31160212 | 0.93 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL16904894 | 0.93 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL31160188 | 0.93 | P2RY6 (0.61) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL18852530 | 0.92 | P2RY6 (0.70) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL565905 | 0.92 | P2RY6 (0.70) | P2RY6P2RY14NT5EABL1RIN1 | |
| SCHEMBL16805383 | 0.92 | P2RY6 (0.70) | P2RY6P2RY14NT5EABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 729 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104647-A1 | VACCINE | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | WO | disclosed |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-12269841-B2 | Production method for oligonucleotides | AJINOMOTO CO., INC. (JP) | 2025-04-08 | — | — | US | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250041400-A1 | RSV VACCINE | ASTRAZENECA PHARMACEUTICALS LP | 2025-02-06 | — | — | US | disclosed |
| WO-2025017142-A1 | RSV VACCINE | ASTRAZENECA AB (SE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2270024-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-5962672-A | OLIGONUCLEOTIDES AGAINST NUCLEIC ACID WHICH CODES FOR SMALL GUANOSINE TRIPHOSPHATASE IMPORTANT IN REGULATION OF CYTOSKELETON DURING CELL CYCLE; FOR ANTICARCINOGENIC/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962671-A | OLIGONUCLEOTIDE WHICH SUPPRESSES GENE EXPRESSION OF FACTOR ASSOCIATED WITH NEUTRAL SPHINGOMYELINASE ACTIVATION; FACTOR IS IS A MEDIATOR OF TUMOR NECROSIS FACTOR ACTIVATION OF THAT ENZYME THROUGH A SIGNAL TRANSDUCTION PATHWAY; GENE THERAPY | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962673-A | ANTISENSE AGENT 8 TO 30 NUCLEOBASES IN LENGTH; FOR DIAGNOSIS AND TREATMENT OF ASTHMA, MYASTHENIA GRAVIS, GRAVES' DISEASE, ALLOGRAFT REJECTION, PSORIASIS AND OTHERS; ANTITUMOR/ ANTIPROLIFERATIVE/ANTIDIABETIC/ANTIARTHRITIC AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5959097-A | OLIGONUCLEOTIDE OF 8 TO 30 NUCLEOTIDES WHICH SUPPRESSES EXPRESSION OF SIGNAL TRANSDUCTION KINASE; FOR TREATMENT OF INFECTIONS; ANTIINFLAMMATORY/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958771-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOTIDES IN LENGTH; FOR DIAGNOSIS AND THERAPY; ANTITUMOR/ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958772-A | TARGETS TO NUCLEIC ACID MOLECULE ENCODING HUMAN CELLULAR INHIBITORS OF APOTOPSIS-1 | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958773-A | ANTISENSE COMPOUND 8 TO 30 NUCLEOTIDES IN LENGTH TARGETED TO A NUCLEIC ACID ENCODING HUMAN AKT-1, OF THE SERINE/THREONINE KINASE FAMILY INVOLVED IN SIGNALLING PATHWAYS; INHIBITING EXPRESSION OF AKT-1 WITH THE ANTISENSE COMPOUND | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5951455-A | OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS WITH MODULATION AND EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948680-A | ANTISENSE OLIGONUCLEOTIDE TARGETED TO NUCLEIC ACIDS ENCODING ELK-1; ANTIPROLIFERATIVE AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5945290-A | OLIGONUCLEOTIDES TARGETED AGAINST SPECIFIC NUCLEIC ACIDS; FOR ANTITUMOR/ANTICARCINOGENIC AGENTS; DIAGNOSIS AND THERAPY OF RELATED DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | P2RY6 2563/4885P2RY14 2588/4885NT5E 163/4885 |
| US-20250041400-A1 | RSV VACCINE | LSS, SLFN12, FDPS | P2RY6 4720/4885P2RY14 4373/4885NT5E 3529/4885 |
| US-12269841-B2 | Production method for oligonucleotides | RNGTT, DCLRE1B, PHOSPHO1 | P2RY6 2497/4885P2RY14 3336/4885NT5E 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.